Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptome data of multiple sclerosis patients receiving fingolimod therapy

ABSTRACT: This SuperSeries is composed of the SubSeries listed below. Using 150 Affymetrix HTA 2.0 microarrays, we profiled the gene expression of 5 cell populations of the peripheral blood from patients with multiple sclerosis in the course of fingolimod treatment.

ORGANISM(S): Homo sapiens

PROVIDER: GSE73174 | GEO | 2015/09/19

SECONDARY ACCESSION(S): PRJNA296075

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcriptome data of multiple sclerosis patients receiving fingolimod therapy [HTA-2_0, CD4+ cells, gene level]

Project description:We analyzed the gene expression patterns of different blood cell types before and during fingolimod treatment in a group of patients with relapsing-remitting multiple sclerosis (RRMS). Affymetrix Human Transcriptome Arrays (HTA) 2.0 were used to obtain gene expression profiles of immune cell populations from 10 RRMS patients within the first 3 months of fingolimod treatment. This GEO entry provides the Affymetrix HTA 2.0 microarray data of peripheral blood CD4+ cells, preprocessed according to the gene level workflow. EDTA blood samples were taken from all patients immediately before first and second fingolimod administration as well as after 3 months of therapy. Total RNA of CD4+ cells positively selected from each blood sample was extracted, labeled and hybridized to high-density Affymetrix HTA 2.0 microarrays to quantify the transcript levels.

2015-09-19 | E-GEOD-73079 | biostudies-arrayexpress

Transcriptome data of multiple sclerosis patients receiving fingolimod therapy [HTA-2_0, CD8+ cells, gene level]

Project description:We analyzed the gene expression patterns of different blood cell types before and during fingolimod treatment in a group of patients with relapsing-remitting multiple sclerosis (RRMS). Affymetrix Human Transcriptome Arrays (HTA) 2.0 were used to obtain gene expression profiles of immune cell populations from 10 RRMS patients within the first 3 months of fingolimod treatment. This GEO entry provides the Affymetrix HTA 2.0 microarray data of peripheral blood CD8+ cells, preprocessed according to the gene level workflow. EDTA blood samples were taken from all patients immediately before first and second fingolimod administration as well as after 3 months of therapy. Total RNA of CD8+ cells positively selected from each blood sample was extracted, labeled and hybridized to high-density Affymetrix HTA 2.0 microarrays to quantify the transcript levels.

2015-09-19 | E-GEOD-73081 | biostudies-arrayexpress

Transcriptome data of multiple sclerosis patients receiving fingolimod therapy [HTA-2_0, CD4+ cells, exon level]

Project description:We analyzed the gene expression patterns of different blood cell types before and during fingolimod treatment in a group of patients with relapsing-remitting multiple sclerosis (RRMS). Affymetrix Human Transcriptome Arrays (HTA) 2.0 were used to obtain gene expression profiles of immune cell populations from 10 RRMS patients within the first 3 months of fingolimod treatment. This GEO entry provides the Affymetrix HTA 2.0 microarray data of peripheral blood CD4+ cells, preprocessed according to the exon level workflow. EDTA blood samples were taken from all patients immediately before first and second fingolimod administration as well as after 3 months of therapy. Total RNA of CD4+ cells positively selected from each blood sample was extracted, labeled and hybridized to high-density Affymetrix HTA 2.0 microarrays to quantify the transcript levels.

2015-09-19 | E-GEOD-73080 | biostudies-arrayexpress

Transcriptome data of multiple sclerosis patients receiving fingolimod therapy [HTA-2_0, CD8+ cells, exon level]

Project description:We analyzed the gene expression patterns of different blood cell types before and during fingolimod treatment in a group of patients with relapsing-remitting multiple sclerosis (RRMS). Affymetrix Human Transcriptome Arrays (HTA) 2.0 were used to obtain gene expression profiles of immune cell populations from 10 RRMS patients within the first 3 months of fingolimod treatment. This GEO entry provides the Affymetrix HTA 2.0 microarray data of peripheral blood CD8+ cells, preprocessed according to the exon level workflow. EDTA blood samples were taken from all patients immediately before first and second fingolimod administration as well as after 3 months of therapy. Total RNA of CD8+ cells positively selected from each blood sample was extracted, labeled and hybridized to high-density Affymetrix HTA 2.0 microarrays to quantify the transcript levels.

2015-09-19 | E-GEOD-73172 | biostudies-arrayexpress

Transcriptome data of multiple sclerosis patients receiving fingolimod therapy [HTA-2_0, CD56+ cells, exon level]

2016-05-20 | GSE81611 | GEO

Transcriptome data of multiple sclerosis patients receiving fingolimod therapy [HTA-2_0, CD56+ cells, gene level]

2016-05-20 | GSE81607 | GEO

Transcriptome data of multiple sclerosis patients receiving fingolimod therapy [HTA-2_0, CD8+ cells, exon level]

2015-09-19 | GSE73172 | GEO

Transcriptome data of multiple sclerosis patients receiving fingolimod therapy [HTA-2_0, CD14+ cells, gene level]

2016-05-20 | GSE81598 | GEO

Transcriptome data of multiple sclerosis patients receiving fingolimod therapy [HTA-2_0, CD8+ cells, gene level]

2015-09-19 | GSE73081 | GEO

Transcriptome data of multiple sclerosis patients receiving fingolimod therapy [HTA-2_0, CD4+ cells, exon level]